Agilent Technologies has entered into a definitive agreement to acquire Proscia, a provider of digital pathology software for clinical and life-sciences customers, in an all-cash transaction valued at USD 240 million in cash at closing and up to an additional USD 30 million based on achieving future performance milestones.

Proscia’s software platform serves as a central operating layer for digital pathology, supporting clinical and life sciences customers across the US and Europe.

By connecting slide scanners, laboratory information systems, image-analysis applications, AI tools, people, and data, Proscia’s innovative technology enables customers to manage images, data, and workflows in one unified environment.

Padraig McDonnell, President and CEO, Agilent, said, “Digital pathology is quickly becoming the foundation for pathology data generation, analysis, and application across biopharmaceutical research, clinical development, and diagnostics, and our acquisition of Proscia meaningfully expands our presence in this fast-growing market.

“The acquisition establishes an Agilent platform for scientific intelligence in tissue-based precision medicine, connecting data generation with AI-based interpretation in a workflow that supports biomarker research through routine clinical use. With Proscia’s leading platform and talented team, we will be better equipped to help laboratories and biopharma customers manage and derive insights from pathology data. We look forward to welcoming the Proscia team to Agilent and working together to accelerate adoption of AI-enabled pathology workflows to advance drug discovery and companion-diagnostics solutions and create long-term value for customers and shareholders,” he added.

The companies entered into a multi-year distribution agreement in September 2022 to offer a comprehensive digital diagnostic-pathology system. The announcement builds on Agilent’s established pathology solutions and its partnership with Proscia.”

David West, Co-Founder and CEO, Proscia, said, “This agreement with Agilent marks an exciting milestone for Proscia and reflects the strength of the platform our team has built. Agilent shares our vision for advancing pathology through open, digital, and AI-enabled solutions. Together, we can accelerate innovation while continuing to provide customers with the flexibility they need across clinical and life sciences workflows. I am grateful to the entire Proscia team, whose dedication made this milestone possible, and look forward to building on our work as part of Agilent.”